Castle Biosciences Reports Second Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Castle Biosciences (CSTL) PT Raised to $35 at BTIG
August 6, 2024 7:31 AM EDTBTIG analyst Sung Ji Nam raised the price target on Castle Biosciences (NASDAQ: CSTL) to $35.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Shares of CSTL are up 12% in the pre-market following a strong 25% Q2 revenue beat and raise to its... More
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance
August 5, 2024 4:20 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of $0.31, $0.58 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $87 million versus the consensus estimate of $69.37 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2024 revenue of $275-300 million, versus the... More
